FDMT — 4D Molecular Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1650648 ·
Last close
$10.79
Market Cap
$608.33M
52W High
$16.93
52W Low
$6.96
ADV30
949,850
Next earnings
2026-11-12
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 4,145,000 — -81,218,000 -78,056,000 428,749,000 39,104,000 90,806,000
Jun 2026 3,781,000 — -77,025,000 -72,936,000 492,615,000 70,372,000 84,956,000
Mar 2026 3,047,000 — -73,620,000 -68,760,000 512,905,000 72,488,000 61,069,000
Dec 2025 85,090,000 — 14,715,000 19,397,000 566,711,000 60,241,000 61,047,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-156,071,000
Investing CF
$-16,637,000
Financing CF
$165,921,000
CapEx
$-697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.04
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-858,000,000
Inventory
—
Receivables
$4,611,000
ST Investments
$290,962,000
EBIT TTM
$-197,115,000
Pretax Income TTM
$-179,175,000
Interest Exp TTM
—
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$96,064,000
EBITDA
$-208,967,008
Free Cash Flow
$-93,785,872
Enterprise Value
$420,944,096
Total Cash
$306,988,992
Total Debt
$38,413,000
Shares Out
56,379,402
Trailing EPS
$-2.70
Book Value
$6.00
ROE
-56.7%
ROA
-31.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 85,209,000 -159,547,000 -140,109,000 566,711,000 61,047,000 505,664,000 -109,082,000
Dec 2024 37,000 -187,841,000 -160,868,000 560,384,000 49,778,000 510,606,000 -134,585,000
Dec 2023 20,723,000 -112,867,000 -100,837,000 339,891,000 32,062,000 307,829,000 -75,792,000
Dec 2022 3,129,000 -110,032,000 -107,494,000 261,846,000 30,509,000 231,337,000 -86,685,000

TTM Snapshot

Revenues TTM
$92,008,000
NetIncome TTM
$-179,175,000
OpCashFlow TTM
—
Assets (Latest)
$492,615,000
Forward EPS
$-4.11

Max Pain — expiry 2027-01-15

max pain strike: $12.00 · spot: $10.46 · call oi: 1,512 · put oi: 2,034
Expected Move to 2027-01-15: ±$3.52 (33.70%) — implied range $6.94 – $13.99 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CGEM Cullinan Therapeutics, Inc. $602.14M $9.27 —
DBVT DBV Technologies S.A. $627.78M $9.99 —
SRZN Surrozen, Inc./DE $571.47M $29.98 —
SANA Sana Biotechnology, Inc. $563.31M $1.88 —
IAM Iambic Therapeutics, Inc. $674.04M $14.22 —

News headlines (Yahoo Finance, 1h cache)

4D Molecular Therapeutics May Benefit From Upcoming Wet AMD Gene Therapy Data, RBC Says
2026-11-16 16:30 · Yahoo
4DMT Announces New Employment Inducement Grants
2026-11-13 21:05 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-12 22:05 · Yahoo
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-11-12 21:05 · Yahoo
4DMT to Participate in Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-11-02 14:00 · Yahoo
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
2026-10-22 11:02 · Yahoo
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
2026-10-21 14:31 · Yahoo
This is the top biotech stock pick from B Riley Securities
2026-09-29 21:24 · Yahoo
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-28 17:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.